{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:48:53Z","timestamp":1794397733050,"version":"4.9.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA134674"],"award-info":[{"award-number":["CA134674"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abnormal serum immunoglobulin (Ig) free light chains (FLC) are established biomarkers of early disease in multiple B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL). Heavy chains have also been shown to be biomarkers in plasma cell disorders. An unanswered question is whether these Ig biomarkers are heritable, i.e., influenced by germline factors. CLL is heritable but highly heterogeneous. Heritable biomarkers could elucidate steps of disease pathogenesis that are affected by germline factors, and may help partition heterogeneity and identify genetic pleiotropies across malignancies. Relatives in CLL pedigrees present an opportunity to identify heritable biomarkers. We compared FLCs and heavy chains between relatives in 23 high-risk CLL pedigrees and population controls. Elevated IgM (eIgM) and abnormal FLC (aFLC) ratio was significantly increased in relatives, suggesting that these Ig biomarkers are heritable and could offer risk stratification in pedigree relatives. Within high-risk CLL pedigrees, B-cell lymphoid malignancies were five times more prevalent in close relatives of individuals with eIgM, prostate cancer was three times more prevalent in relatives of individuals with aFLC, and monoclonal B-cell lymphocytosis increased surrounding individuals with normal Ig levels. These different clustering patterns suggest Ig biomarkers have the potential to partition genetic heterogeneity in CLL and provide insight into distinct heritable pleiotropies associated with CLL.<\/jats:p>","DOI":"10.1038\/s41408-019-0186-8","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T16:04:16Z","timestamp":1551197056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees"],"prefix":"10.1038","volume":"9","author":[{"given":"Martha J.","family":"Glenn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7200-6706","authenticated-orcid":false,"given":"Michael J.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra D.","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandt","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4788-1998","authenticated-orcid":false,"given":"Nicola J.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"186_CR1","unstructured":"Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL) [Internet]. [cited 2018]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"186_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-2141.2007.06874.x","volume":"139","author":"A Blair","year":"2007","unstructured":"Blair, A., Purdue, M. P., Weisenburger, D. D. & Baris, D. Chemical exposures and risk of chronic lymphocytic leukaemia. Br. J. Haematol. 139, 753\u2013761 (2007).","journal-title":"Br. J. Haematol."},{"key":"186_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-138","volume":"12","author":"F Albright","year":"2012","unstructured":"Albright, F., Teerlink, C., Werner, T. L. & Cannon-Albright, L. A. Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer 12, 138 (2012).","journal-title":"BMC Cancer"},{"key":"186_CR4","first-page":"2378","volume":"54","author":"LA Cannon-Albright","year":"1994","unstructured":"Cannon-Albright, L. A. et al. Familiality of cancer in Utah. Cancer Res. 54, 2378\u20132385 (1994).","journal-title":"Cancer Res."},{"key":"186_CR5","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/jnci\/86.21.1600","volume":"86","author":"DE Goldgar","year":"1994","unstructured":"Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A. & Skolnick, M. H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J. Natl Cancer Inst. 86, 1600\u20131608 (1994).","journal-title":"J. Natl Cancer Inst."},{"key":"186_CR6","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1182\/blood-2004-01-0341","volume":"104","author":"LR Goldin","year":"2004","unstructured":"Goldin, L. R., Pfeiffer, R. M., Li, X. & Hemminki, K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 104, 1850\u20131854 (2004).","journal-title":"Blood"},{"key":"186_CR7","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/cncr.20989","volume":"103","author":"RA Kerber","year":"2005","unstructured":"Kerber, R. A. & O\u2019Brien, E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer 103, 1906\u20131915 (2005).","journal-title":"Cancer"},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","volume":"1","author":"EE Sigurdardottir","year":"2015","unstructured":"Sigurdardottir, E. E. et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple mmyeloma. JAMA Oncol 1, 168\u2013174 (2015).","journal-title":"JAMA Oncol"},{"key":"186_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248\u2013262 (2017).","journal-title":"Cell Rep."},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1056\/NEJMoa0806122","volume":"360","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. B-cell clones as early markers for chronic lymphocytic leukemia. N. Engl. J. Med. 360, 659\u2013667 (2009).","journal-title":"N. Engl. J. Med."},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1365-2141.2010.08339.x","volume":"151","author":"LR Goldin","year":"2010","unstructured":"Goldin, L. R. et al. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br. J. Haematol. 151, 152\u2013158 (2010).","journal-title":"Br. J. Haematol."},{"key":"186_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1182\/blood.V100.2.635","volume":"100","author":"AC Rawstron","year":"2002","unstructured":"Rawstron, A. C. et al. Monoclonal B lymphocytes with the characteristics of \u201cindolent\u201d chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 100, 635\u2013639 (2002).","journal-title":"Blood"},{"key":"186_CR13","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood-2003-09-3277","volume":"103","author":"P Ghia","year":"2004","unstructured":"Ghia, P. et al. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 103, 2337\u20132342 (2004).","journal-title":"Blood"},{"key":"186_CR14","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/leu.2008.171","volume":"22","author":"CL Snozek","year":"2008","unstructured":"Snozek, C. L. et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 22, 1933\u20131937 (2008).","journal-title":"Leukemia"},{"key":"186_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1365-2141.2004.05169.x","volume":"127","author":"SV Rajkumar","year":"2004","unstructured":"Rajkumar, S. V. et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br. J. Haematol. 127, 308\u2013310 (2004).","journal-title":"Br. J. Haematol."},{"key":"186_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2141.2007.06561.x","volume":"137","author":"MC Kyrtsonis","year":"2007","unstructured":"Kyrtsonis, M. C. et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br. J. Haematol. 137, 240\u2013243 (2007).","journal-title":"Br. J. Haematol."},{"key":"186_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2007-01-067728","volume":"110","author":"F van Rhee","year":"2007","unstructured":"van Rhee, F. et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110, 827\u2013832 (2007).","journal-title":"Blood"},{"key":"186_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.7754\/Clin.Lab.2017.171040","volume":"64","author":"Y Meddour","year":"2018","unstructured":"Meddour, Y. et al. Serum free light chain predict overall survival and response to therapy in patients with newly diagnosed multiple myeloma. Clin. Lab. 64, 551\u2013558 (2018).","journal-title":"Clin. Lab."},{"key":"186_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2141.2008.07456.x","volume":"144","author":"G Pratt","year":"2009","unstructured":"Pratt, G. et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br. J. Haematol. 144, 217\u2013222 (2009).","journal-title":"Br. J. Haematol."},{"key":"186_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1600-0609.2010.01412.x","volume":"84","author":"ZA Yegin","year":"2010","unstructured":"Yegin, Z. A., Ozkurt, Z. N. & Yagci, M. Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia. Eur. J. Haematol. 84, 406\u2013411 (2010).","journal-title":"Eur. J. Haematol."},{"key":"186_CR21","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1182\/blood-2011-04-349134","volume":"118","author":"MJ Maurer","year":"2011","unstructured":"Maurer, M. J. et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 118, 2821\u20132826 (2011).","journal-title":"Blood"},{"key":"186_CR22","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1182\/blood-2011-04-345587","volume":"118","author":"F Morabito","year":"2011","unstructured":"Morabito, F. et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood 118, 6353\u20136361 (2011).","journal-title":"Blood"},{"key":"186_CR23","doi-asserted-by":"publisher","first-page":"359071","DOI":"10.1155\/2013\/359071","volume":"2013","author":"K Sarris","year":"2013","unstructured":"Sarris, K. et al. Prognostic significance of serum free light chains in chronic lymphocytic leukemia. Adv. Hematol. 2013, 359071 (2013).","journal-title":"Adv. Hematol."},{"key":"186_CR24","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/ajh.23839","volume":"89","author":"TE Witzig","year":"2014","unstructured":"Witzig, T. E. et al. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma. Am. J. Hematol. 89, 1116\u20131120 (2014).","journal-title":"Am. J. Hematol."},{"key":"186_CR25","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1182\/blood-2009-08-237651","volume":"114","author":"HT Tsai","year":"2009","unstructured":"Tsai, H. T. et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 114, 4928\u20134932 (2009).","journal-title":"Blood"},{"key":"186_CR26","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1373\/clinchem.2009.123828","volume":"55","author":"AR Bradwell","year":"2009","unstructured":"Bradwell, A. R. et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa\/lambda ratios. Clin. Chem. 55, 1646\u20131655 (2009).","journal-title":"Clin. Chem."},{"key":"186_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/leu.2012.159","volume":"27","author":"A Bradwell","year":"2013","unstructured":"Bradwell, A. et al. Prognostic utility of intact immunoglobulin Ig\u2019kappa\/Ig\u2019lambda ratios in multiple myeloma patients. Leukemia 27, 202\u2013207 (2013).","journal-title":"Leukemia"},{"key":"186_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/leu.2012.197","volume":"27","author":"H Ludwig","year":"2013","unstructured":"Ludwig, H. et al. Immunoglobulin heavy\/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 27, 213\u2013219 (2013).","journal-title":"Leukemia"},{"key":"186_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/ejh.12682","volume":"97","author":"C Wang","year":"2016","unstructured":"Wang, C. et al. Prognostic value of serum heavy\/light chain ratios in patients with POEMS syndrome. Eur. J. Haematol. 97, 48\u201354 (2016).","journal-title":"Eur. J. Haematol."},{"key":"186_CR30","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.clml.2016.02.034","volume":"16","author":"L Magnano","year":"2016","unstructured":"Magnano, L. et al. Prognostic impact of serum heavy\/light chain pairs in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma: long-term results from a single institution. Clin. Lymphoma Myeloma Leuk. 16, e71\u2013e77 (2016).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"186_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.12958","volume":"99","author":"C Greil","year":"2017","unstructured":"Greil, C. et al. The serum heavy\/light chain immunoassay: a valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. Eur. J. Haematol. 99, 449\u2013458 (2017).","journal-title":"Eur. J. Haematol."},{"key":"186_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/10428194.2017.1339876","volume":"59","author":"G Fouquet","year":"2018","unstructured":"Fouquet, G. et al. Heavy+light chain analysis to assign myeloma response is analogous to the IMWG response criteria. Leuk. Lymphoma 59, 583\u2013589 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"186_CR33","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","volume":"48","author":"JA Katzmann","year":"2002","unstructured":"Katzmann, J. A. et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin. Chem. 48, 1437\u20131444 (2002).","journal-title":"Clin. Chem."},{"key":"186_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/leu.2012.189","volume":"27","author":"JA Katzmann","year":"2013","unstructured":"Katzmann, J. A. et al. Suppression of uninvolved immunoglobulins defined by heavy\/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 27, 208\u2013212 (2013).","journal-title":"Leukemia"},{"key":"186_CR35","doi-asserted-by":"crossref","unstructured":"Hosmer D. W. L. S., Sturdivant R. X. Applied Logistic Regression. 3rd edn (John Wiley & Sons Inc., Hoboken, NJ, 2013).","DOI":"10.1002\/9781118548387"},{"key":"186_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 80, 27\u201338 (1993).","journal-title":"Biometrika"},{"issue":"Suppl 1","key":"186_CR37","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1007\/s10875-014-0025-4","volume":"34","author":"C Gronwall","year":"2014","unstructured":"Gronwall, C. & Silverman, G. J. Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J. Clin. Immunol. 34(Suppl 1), S12\u2013S21 (2014).","journal-title":"J. Clin. Immunol."},{"key":"186_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.molimm.2004.07.045","volume":"42","author":"Y Peng","year":"2005","unstructured":"Peng, Y., Kowalewski, R., Kim, S. & Elkon, K. B. The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol. Immunol. 42, 781\u2013787 (2005).","journal-title":"Mol. Immunol."},{"key":"186_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12026-015-8708-3","volume":"63","author":"M Aziz","year":"2015","unstructured":"Aziz, M., Holodick, N. E., Rothstein, T. L. & Wang, P. The role of B-1 cells in inflammation. Immunol. Res. 63, 153\u2013166 (2015).","journal-title":"Immunol. Res."},{"key":"186_CR40","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"K Ekstrom Smedby","year":"2008","unstructured":"Ekstrom Smedby, K. et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111, 4029\u20134038 (2008).","journal-title":"Blood"},{"key":"186_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/jnci\/djq043","volume":"102","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson, S. Y. et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J. Natl Cancer Inst. 102, 557\u2013567 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"186_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","volume":"2014","author":"LM Morton","year":"2014","unstructured":"Morton, L. M. et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl Cancer Inst. Monogr. 2014, 130\u2013144 (2014).","journal-title":"J. Natl Cancer Inst. Monogr."},{"key":"186_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3816\/CLM.2009.n.003","volume":"9","author":"ML McMaster","year":"2009","unstructured":"McMaster, M. L., Kristinsson, S. Y., Turesson, I., Bjorkholm, M. & Landgren, O. Novel aspects pertaining to the relationship of Waldenstrom\u2019s macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia. Clin. Lymphoma Myeloma 9, 19\u201322 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"186_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14175","volume":"8","author":"PJ Law","year":"2017","unstructured":"Law, P. J. et al. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat. Commun. 8, 14175 (2017).","journal-title":"Nat. Commun."},{"key":"186_CR45","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/hmg\/ddy094","volume":"27","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia. Hum. Mol. Genet. 27, 1809\u20131818 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"186_CR46","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2326-6066.CIR-17-0582","volume":"6","author":"CH Tang","year":"2018","unstructured":"Tang, C. H. et al. Secretory IgM exacerbates tumor progression by inducing accumulations of MDSCs in mice. Cancer Immunol. Res. 6, 696\u2013710 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"186_CR47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0145-2126(91)90005-E","volume":"15","author":"LM Pottern","year":"1991","unstructured":"Pottern, L. M. et al. Familial cancers associated with subtypes of leukemia and non-Hodgkin\u2019s lymphoma. Leuk. Res. 15, 305\u2013314 (1991).","journal-title":"Leuk. Res."},{"key":"186_CR48","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/ijc.22414","volume":"120","author":"O Landgren","year":"2007","unstructured":"Landgren, O. et al. Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int. J. Cancer 120, 1099\u20131102 (2007).","journal-title":"Int. J. Cancer"},{"key":"186_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/gim.2011.2","volume":"14","author":"CC Teerlink","year":"2012","unstructured":"Teerlink, C. C., Albright, F. S., Lins, L. & Cannon-Albright, L. A. A comprehensive survey of cancer risks in extended families. Genet. Med. 14, 107\u2013114 (2012).","journal-title":"Genet. Med."},{"key":"186_CR50","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1600-0609.1994.tb00192.x","volume":"53","author":"A Mellemgaard","year":"1994","unstructured":"Mellemgaard, A., Geisler, C. H. & Storm, H. H. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia. Eur. J. Haematol. 53, 218\u2013222 (1994).","journal-title":"Eur. J. Haematol."},{"key":"186_CR51","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","volume":"27","author":"AM Tsimberidou","year":"2009","unstructured":"Tsimberidou, A. M. et al. Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma. J. Clin. Oncol. 27, 904\u2013910 (2009).","journal-title":"J. Clin. Oncol."},{"key":"186_CR52","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/annonc\/mdw072","volume":"27","author":"L Falchi","year":"2016","unstructured":"Falchi, L. et al. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann. Oncol. 27, 1100\u20131106 (2016).","journal-title":"Ann. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0186-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:10:04Z","timestamp":1671207004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0186-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"19 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"25"}}